Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 14Lymphoma, Large B-Cell, Diffuse 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Follicular 10Lymphoma 10Leukemia, Lymphocytic, Chronic, B-Cell 10Leukemia 9Lymphoma, Large-Cell, Immunoblastic 8Hodgkin Disease 8Burkitt Lymphoma 8Lymphoma, Mantle-Cell 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, T-Cell, Cutaneous 6Lymphoma, B-Cell, Marginal Zone 6Sezary Syndrome 5Mycosis Fungoides 5Lymphoma, Large-Cell, Anaplastic 5Waldenstrom Macroglobulinemia 4Immunoblastic Lymphadenopathy 4Colorectal Neoplasms 4Pancreatic Neoplasms 3Multiple Myeloma 3Lymphoma, T-Cell, Peripheral 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Carcinoma, Non-Small-Cell Lung 3Sarcoma 2Neoplasm Metastasis 2Lymphoma, Extranodal NK-T-Cell 2Leukemia-Lymphoma, Adult T-Cell 2

Interventions

Dexamethasone 3filanesib 2Steroids 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2pomalidomide 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Proteasome Inhibitors 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Melphalan 1Gemcitabine 1Calcium Dobesilate 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Plasmacytoma × Gemcitabine × Other hematologic neoplasm × Clear all
NCT02506959 2025-03-18

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

M.D. Anderson Cancer Center

Phase 2 Completed
83 enrolled 11 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡